Enara Bio Secures $32.5 Million in Series B Funding
Enara Bio, a groundbreaking biotechnology company based in Oxford, UK, has recently announced a significant funding achievement, successfully raising $32.5 million in its Series B funding round. This impressive financial milestone was led by prominent investors, Pfizer Ventures and M Ventures, who played a crucial role in securing the capital. Additionally, existing investors, including RA Capital, Samsara BioCapital, and SV Health Investors, also participated in this funding effort. Notably, the Francis Crick Institute has joined as a new investor, further enhancing the financial backing for the company’s innovative endeavors.
In conjunction with this financing round, Enara Bio has made strategic enhancements to its Board of Directors, appointing key figures who are expected to bolster the company’s governance and strategic direction.
Rana Al-Hallaq, a Partner at Pfizer Ventures, and Bauke Anninga, an Investment Director at M Ventures, have been appointed to the board, bringing a wealth of experience and expertise. With these developments, Enara Bio is poised to utilize the newly acquired funds to accelerate its pipeline of T-cell receptor (TCR)-based immunotherapies, focusing on novel and differentiated Dark Antigen targets specifically designed for the treatment of solid tumors.
At the helm of this progressive company is Kevin Pojasek, who serves as CEO and President. Under his leadership, Enara Bio has established an innovative platform known as EDAPT, which is revolutionizing the discovery and validation process of Dark Antigen targets. This platform integrates cutting-edge bioinformatics databases with immunopeptidomics techniques applied to both tumor and healthy tissues, alongside advanced RNA in situ hybridization methods. This comprehensive approach not only confirms the presentation of Dark Antigens on the surface of human tumor cells but also validates their cancer-specific properties and demonstrates their consistent expression within tumors. Such advancements hold great promise for the future of cancer immunotherapy and could lead to significant breakthroughs in treatment options for patients battling this disease.
They've invested in Enara Bio
Get to know these Healthtech investors
| # | Investor | Sector | Stage | Activity | Team | Connect |
|---|---|---|---|---|---|---|
1 |  Pfizer Ventures | 2 investment(s) investment(s) | 7 contacts contacts | |||
2 |  M Ventures | 7 investment(s) investment(s) | 19 contacts contacts | |||
3 |  RA Capital | 1 investment(s) investment(s) | more info | |||
4 |  Samsara BioCapital | 1 investment(s) investment(s) | more info | |||
5 |  SV Health Investors | 3 investment(s) investment(s) | more info | |||
6 |  Francis Crick Institute | investment(s) investment(s) | more info |
Click here for a full list of 6,908+ startup investors in the UK